Skip to main content

Fungal Infections

7
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 8 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
4 programs
2
1
PosaconazolePhase 3Small Molecule
Posaconazole 12 mg/kg/day BIDPhase 1
Posaconazole 200 mgPhase 1
Posaconazole oral suspension 40 mg/mLN/A
MSD
MSDIreland - Ballydine
4 programs
2
1
PosaconazolePhase 3Small Molecule1 trial
Posaconazole 12 mg/kg/day BIDPhase 11 trial
Posaconazole 200 mgPhase 11 trial
Posaconazole oral suspension 40 mg/mLN/A1 trial
Active Trials
NCT01436578Completed273Est. Nov 2013
NCT01716234Terminated142Est. Apr 2015
NCT01777763Completed230Est. Feb 2012
+1 more trials
Astellas
AstellasChina - Shenyang
1 program
1
MicafunginPhase 11 trial
Active Trials
NCT00606268Completed42Est. Mar 2009
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Studies of Disorders With Increased Susceptibility to Fungal InfectionsN/A1 trial
Active Trials
NCT01222741Recruiting850

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDPosaconazole
MSDPosaconazole 200 mg
MSDPosaconazole 12 mg/kg/day BID
AstellasMicafungin
MSDPosaconazole oral suspension 40 mg/mL
Allergy TherapeuticsStudies of Disorders With Increased Susceptibility to Fungal Infections

Clinical Trials (6)

Total enrollment: 2,122 patients across 6 trials

NCT01782131MSDPosaconazole

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Start: Sep 2013Est. completion: Sep 2019585 patients
Phase 3Completed
NCT01777763MSDPosaconazole 200 mg

Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

Start: Jun 2009Est. completion: Feb 2012230 patients
Phase 1Completed
NCT01716234MSDPosaconazole 12 mg/kg/day BID

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Start: Apr 2008Est. completion: Apr 2015142 patients
Phase 1Terminated
NCT00606268AstellasMicafungin

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

Start: Nov 2007Est. completion: Mar 200942 patients
Phase 1Completed
NCT01436578MSDPosaconazole oral suspension 40 mg/mL

Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)

Start: Feb 2012Est. completion: Nov 2013273 patients
N/ACompleted
NCT01222741Allergy TherapeuticsStudies of Disorders With Increased Susceptibility to Fungal Infections

Studies of Disorders With Increased Susceptibility to Fungal Infections

Start: Jan 2011850 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,122 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.